These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9207432)

  • 1. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.
    Villunger A; Egle A; Marschitz I; Kos M; Böck G; Ludwig H; Geley S; Kofler R; Greil R
    Blood; 1997 Jul; 90(1):12-20. PubMed ID: 9207432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
    Tinhofer I; Marschitz I; Kos M; Henn T; Egle A; Villunger A; Greil R
    Blood; 1998 Jun; 91(11):4273-81. PubMed ID: 9596676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
    Villunger A; Egle A; Kos M; Hartmann BL; Geley S; Kofler R; Greil R
    Cancer Res; 1997 Aug; 57(16):3331-4. PubMed ID: 9269989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.
    Frassanito MA; Silvestris F; Silvestris N; Cafforio P; Camarda G; Iodice G; Dammacco F
    Clin Exp Immunol; 1998 Nov; 114(2):179-88. PubMed ID: 9822274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
    von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
    Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients.
    Buzyn A; Petit F; Ostankovitch M; Figueiredo S; Varet B; Guillet JG; Ameisen JC; Estaquier J
    Blood; 1999 Nov; 94(9):3135-40. PubMed ID: 10556200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
    Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
    Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines.
    Rajashekhar G; Loganath A; Roy AC; Mongelli JM
    Gynecol Oncol; 2003 Oct; 91(1):101-11. PubMed ID: 14529668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
    Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
    Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
    Peduto Eberl L; Guillou L; Saraga E; Schröter M; French LE; Tschopp J; Juillerat-Jeanneret L
    Int J Cancer; 1999 May; 81(5):772-8. PubMed ID: 10328232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
    Rensing-Ehl A; Frei K; Flury R; Matiba B; Mariani SM; Weller M; Aebischer P; Krammer PH; Fontana A
    Eur J Immunol; 1995 Aug; 25(8):2253-8. PubMed ID: 7545115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
    Hoves S; Krause SW; Halbritter D; Zhang HG; Mountz JD; Schölmerich J; Fleck M
    J Immunol; 2003 Jun; 170(11):5406-13. PubMed ID: 12759415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis.
    Frei K; Ambar B; Adachi N; Yonekawa Y; Fontana A
    J Neuroimmunol; 1998 Jul; 87(1-2):105-13. PubMed ID: 9670851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
    O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
    Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha and interferon-gamma induce expression of functional Fas ligand on HT29 and MCF7 adenocarcinoma cells.
    Naujokat C; Sezer O; Possinger K
    Biochem Biophys Res Commun; 1999 Nov; 264(3):813-9. PubMed ID: 10544014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo.
    Aung S; Graham BS
    J Immunol; 2000 Apr; 164(7):3487-93. PubMed ID: 10725701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
    O'Connell J; O'Sullivan GC; Collins JK; Shanahan F
    J Exp Med; 1996 Sep; 184(3):1075-82. PubMed ID: 9064324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions.
    Sikora J; Dworacki G; Zeromski J
    Nat Immun; 1998; 16(5-6):244-55. PubMed ID: 11061592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and function of Fas and Fas ligand on peripheral blood lymphocytes in normal subjects.
    Kawakami A; Eguchi K; Matsuoka N; Tsuboi M; Koji T; Urayama S; Nakashima T; Kawabe Y; Nagataki S
    J Lab Clin Med; 1998 Nov; 132(5):404-13. PubMed ID: 9823934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.